Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer

Tomoyasu Yoshihiro, Hitoshi Kusaba, Akitaka Makiyama, Kazuma Kobayashi, Masato Uenomachi, Mamoru Ito, Yasuhiro Doi, Kenji Mitsugi, Tomomi Aikawa, Kotoe Takayoshi, Taito Esaki, Hozumi Shimokawa, Kenji Tsuchihashi, hiroshi ariyama, Koichi Akashi, Eishi Baba

研究成果: ジャーナルへの寄稿記事

抄録

Background: Dose modification of chemotherapy for metastatic colorectal cancer (MCRC) is often needed, especially in second-line and later-line treatments due to adverse events of previous treatment and poor patient condition. No study has focused on ramucirumab plus modified dose of FOLFIRI for MCRC, and whether low relative dose intensity (RDI) affects treatment efficacy has not been clarified. Methods: MCRC patients who received ramucirumab plus FOLFIRI, which consisted of 150 mg/m 2 of irinotecan, at six institutions were retrospectively analyzed. Results: A total of 43 patients were assessed. Median age was 63 years, and 22 patients (51%) were women. Twenty-six patients (60%) were given ramucirumab plus FOLFIRI as second-line therapy, and 17 (40%) as third or later-line. The median relative dose intensity (RDI) of irinotecan was 60.6%, which is lower than that in the pivotal phase 3 study (RAISE), and other agents showed the same trend. Median progression-free survival was 4.8 [95% confidence interval (CI) 3.2–5.7] months for all patients, 5.4 (95% CI 3.5–7.2) months for second-line patients, and 2.8 (95% CI 1.6–5.8) months for third or later-line patients. Median overall survival was 17.3 (95% CI 11.5–22.4) months for all patients. Patients with irinotecan RDI less than 60% showed similar treatment efficacy. Hematological toxicities of grade 3 or worse were observed in 21 patients, but all were manageable. Conclusion: Low RDI did not compromise the treatment efficacy of ramucirumab plus modified FOLFIRI for MCRC patients.

元の言語英語
ページ(範囲)508-515
ページ数8
ジャーナルInternational Journal of Clinical Oncology
24
発行部数5
DOI
出版物ステータス出版済み - 5 15 2019

Fingerprint

Colorectal Neoplasms
Safety
irinotecan
Confidence Intervals
ramucirumab
Disease-Free Survival
Therapeutics
Drug Therapy
Survival

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hematology
  • Oncology

これを引用

Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer. / Yoshihiro, Tomoyasu; Kusaba, Hitoshi; Makiyama, Akitaka; Kobayashi, Kazuma; Uenomachi, Masato; Ito, Mamoru; Doi, Yasuhiro; Mitsugi, Kenji; Aikawa, Tomomi; Takayoshi, Kotoe; Esaki, Taito; Shimokawa, Hozumi; Tsuchihashi, Kenji; ariyama, hiroshi; Akashi, Koichi; Baba, Eishi.

:: International Journal of Clinical Oncology, 巻 24, 番号 5, 15.05.2019, p. 508-515.

研究成果: ジャーナルへの寄稿記事

Yoshihiro, T, Kusaba, H, Makiyama, A, Kobayashi, K, Uenomachi, M, Ito, M, Doi, Y, Mitsugi, K, Aikawa, T, Takayoshi, K, Esaki, T, Shimokawa, H, Tsuchihashi, K, ariyama, H, Akashi, K & Baba, E 2019, 'Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer', International Journal of Clinical Oncology, 巻. 24, 番号 5, pp. 508-515. https://doi.org/10.1007/s10147-018-01391-w
Yoshihiro, Tomoyasu ; Kusaba, Hitoshi ; Makiyama, Akitaka ; Kobayashi, Kazuma ; Uenomachi, Masato ; Ito, Mamoru ; Doi, Yasuhiro ; Mitsugi, Kenji ; Aikawa, Tomomi ; Takayoshi, Kotoe ; Esaki, Taito ; Shimokawa, Hozumi ; Tsuchihashi, Kenji ; ariyama, hiroshi ; Akashi, Koichi ; Baba, Eishi. / Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer. :: International Journal of Clinical Oncology. 2019 ; 巻 24, 番号 5. pp. 508-515.
@article{974f72eb307e4d9ab6a63000ae95cec8,
title = "Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer",
abstract = "Background: Dose modification of chemotherapy for metastatic colorectal cancer (MCRC) is often needed, especially in second-line and later-line treatments due to adverse events of previous treatment and poor patient condition. No study has focused on ramucirumab plus modified dose of FOLFIRI for MCRC, and whether low relative dose intensity (RDI) affects treatment efficacy has not been clarified. Methods: MCRC patients who received ramucirumab plus FOLFIRI, which consisted of 150 mg/m 2 of irinotecan, at six institutions were retrospectively analyzed. Results: A total of 43 patients were assessed. Median age was 63 years, and 22 patients (51{\%}) were women. Twenty-six patients (60{\%}) were given ramucirumab plus FOLFIRI as second-line therapy, and 17 (40{\%}) as third or later-line. The median relative dose intensity (RDI) of irinotecan was 60.6{\%}, which is lower than that in the pivotal phase 3 study (RAISE), and other agents showed the same trend. Median progression-free survival was 4.8 [95{\%} confidence interval (CI) 3.2–5.7] months for all patients, 5.4 (95{\%} CI 3.5–7.2) months for second-line patients, and 2.8 (95{\%} CI 1.6–5.8) months for third or later-line patients. Median overall survival was 17.3 (95{\%} CI 11.5–22.4) months for all patients. Patients with irinotecan RDI less than 60{\%} showed similar treatment efficacy. Hematological toxicities of grade 3 or worse were observed in 21 patients, but all were manageable. Conclusion: Low RDI did not compromise the treatment efficacy of ramucirumab plus modified FOLFIRI for MCRC patients.",
author = "Tomoyasu Yoshihiro and Hitoshi Kusaba and Akitaka Makiyama and Kazuma Kobayashi and Masato Uenomachi and Mamoru Ito and Yasuhiro Doi and Kenji Mitsugi and Tomomi Aikawa and Kotoe Takayoshi and Taito Esaki and Hozumi Shimokawa and Kenji Tsuchihashi and hiroshi ariyama and Koichi Akashi and Eishi Baba",
year = "2019",
month = "5",
day = "15",
doi = "10.1007/s10147-018-01391-w",
language = "English",
volume = "24",
pages = "508--515",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer

AU - Yoshihiro, Tomoyasu

AU - Kusaba, Hitoshi

AU - Makiyama, Akitaka

AU - Kobayashi, Kazuma

AU - Uenomachi, Masato

AU - Ito, Mamoru

AU - Doi, Yasuhiro

AU - Mitsugi, Kenji

AU - Aikawa, Tomomi

AU - Takayoshi, Kotoe

AU - Esaki, Taito

AU - Shimokawa, Hozumi

AU - Tsuchihashi, Kenji

AU - ariyama, hiroshi

AU - Akashi, Koichi

AU - Baba, Eishi

PY - 2019/5/15

Y1 - 2019/5/15

N2 - Background: Dose modification of chemotherapy for metastatic colorectal cancer (MCRC) is often needed, especially in second-line and later-line treatments due to adverse events of previous treatment and poor patient condition. No study has focused on ramucirumab plus modified dose of FOLFIRI for MCRC, and whether low relative dose intensity (RDI) affects treatment efficacy has not been clarified. Methods: MCRC patients who received ramucirumab plus FOLFIRI, which consisted of 150 mg/m 2 of irinotecan, at six institutions were retrospectively analyzed. Results: A total of 43 patients were assessed. Median age was 63 years, and 22 patients (51%) were women. Twenty-six patients (60%) were given ramucirumab plus FOLFIRI as second-line therapy, and 17 (40%) as third or later-line. The median relative dose intensity (RDI) of irinotecan was 60.6%, which is lower than that in the pivotal phase 3 study (RAISE), and other agents showed the same trend. Median progression-free survival was 4.8 [95% confidence interval (CI) 3.2–5.7] months for all patients, 5.4 (95% CI 3.5–7.2) months for second-line patients, and 2.8 (95% CI 1.6–5.8) months for third or later-line patients. Median overall survival was 17.3 (95% CI 11.5–22.4) months for all patients. Patients with irinotecan RDI less than 60% showed similar treatment efficacy. Hematological toxicities of grade 3 or worse were observed in 21 patients, but all were manageable. Conclusion: Low RDI did not compromise the treatment efficacy of ramucirumab plus modified FOLFIRI for MCRC patients.

AB - Background: Dose modification of chemotherapy for metastatic colorectal cancer (MCRC) is often needed, especially in second-line and later-line treatments due to adverse events of previous treatment and poor patient condition. No study has focused on ramucirumab plus modified dose of FOLFIRI for MCRC, and whether low relative dose intensity (RDI) affects treatment efficacy has not been clarified. Methods: MCRC patients who received ramucirumab plus FOLFIRI, which consisted of 150 mg/m 2 of irinotecan, at six institutions were retrospectively analyzed. Results: A total of 43 patients were assessed. Median age was 63 years, and 22 patients (51%) were women. Twenty-six patients (60%) were given ramucirumab plus FOLFIRI as second-line therapy, and 17 (40%) as third or later-line. The median relative dose intensity (RDI) of irinotecan was 60.6%, which is lower than that in the pivotal phase 3 study (RAISE), and other agents showed the same trend. Median progression-free survival was 4.8 [95% confidence interval (CI) 3.2–5.7] months for all patients, 5.4 (95% CI 3.5–7.2) months for second-line patients, and 2.8 (95% CI 1.6–5.8) months for third or later-line patients. Median overall survival was 17.3 (95% CI 11.5–22.4) months for all patients. Patients with irinotecan RDI less than 60% showed similar treatment efficacy. Hematological toxicities of grade 3 or worse were observed in 21 patients, but all were manageable. Conclusion: Low RDI did not compromise the treatment efficacy of ramucirumab plus modified FOLFIRI for MCRC patients.

UR - http://www.scopus.com/inward/record.url?scp=85059697938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059697938&partnerID=8YFLogxK

U2 - 10.1007/s10147-018-01391-w

DO - 10.1007/s10147-018-01391-w

M3 - Article

VL - 24

SP - 508

EP - 515

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 5

ER -